Brokerages forecast that Mylan N.V. (NASDAQ:MYL) will report $1.19 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Looking back over the last month, shares have performed -14.92%.
Mylan's quarterly net earnings rose 76.4 per cent to $297 million, or 55 USA cents per share, helped by demand for products it gained through the acquisition of Swedish drugmaker Meda past year. Mylan N.V. The firm's quarterly revenue was up 24.1% on a year-over-year basis. The stock rose 0.68% or $0.22 reaching $32.22 per share. Bank of The West raised its position in shares of Mylan N.V.by 4.9% in the first quarter.
Weighted Alpha is used to calculate how much a share has gone up or down over a certain period, normally a year. TIAA CREF Investment Management LLC increased its stake in shares of Mylan N.V.by 187.3% in the first quarter. As of quarter end Zurcher Kantonalbank (zurich Cantonalbank) had disposed of a total of 93,365 shares trimming its stake by 44.4%. Russell Investments Group Ltd. owned about 0.28% of Mylan N.V. worth $58,765,000 as of its most recent filing with the SEC. At the time of writing, Shares the company recently traded -2.35% away 52-week low and noted price movement -36.51% away from the 52-week high level. Investors may also be paying close concentration to some simple moving average indicators on shares of Mylan N.V. (MYL).
The P/E ratio is 31.76 and the market cap is 17.04B. Mylan N.V. also was the recipient of some unusual options trading on Monday. Stock investors acquired 9,410 call options on the stock. This is an increase of approximately 250% compared to the typical volume of 2,688 call options.
Mylan N.V., launched on July 7, 2014, is a global pharmaceutical company. (NASDAQ:MYL) last posted its earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.92 by $0.01.Читайте также: Ubisoft to Open New Studio in Stockholm
Sell-side analysts have also provided a consensus recommendation of 2.10 on company shares. During the same period in the prior year, the firm earned $0.76 earnings per share. Next quarter's EPS is expected be $1.44 with next year's EPS projected to be $5.64.
TRADEMARK VIOLATION NOTICE: This article was posted by Week Herald and is the property of of Week Herald. The correct version of this news story can be accessed at https://theolympiareport.com/2017/08/08/bidaskclub-downgrades-mylan-n-v-nasdaqmyl-to-sell.html. Mylan Inc. had 37 analyst reports since July 27, 2015 according to SRatingsIntel.
Ratings analysis reveals 65% of Mylan Inc.'s analysts are positive. Cowen and Company reissued a "hold" rating and issued a $43.00 target price on shares of Mylan N.V.in a research note on Thursday, August 3rd. BidaskClub cut Mylan N.V. from a "hold" rating to a "sell" rating in a report on Saturday. BMO Capital Markets started coverage on shares of Mylan N.V.in a report on Monday, May 1st.
The price of Mylan stock fell 9.09 percent, to $28.90 per share, in pre-market trading on Wednesday. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Shares price moved down from its 50 days moving average with -12.73% and remote positively from 200 days moving average with -11.23%. Insiders now own 0.40% of total outstanding shares. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
In related news, President Rajiv Malik sold 25,000 shares of the stock in a transaction on Friday, June 9th. 249 shares valued at $44,225 were sold by Oliveira Orlando on Wednesday, March 1. Nisa Investment Advisors LLC now owns 82,107 shares of the company's stock worth $3,201,000 after buying an additional 550 shares during the period. The disclosure for this sale can be found here. The Company conducts active pharmaceutical ingredient (API) business through Mylan Laboratories Limited (Mylan India). The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. On Tuesday, Mallinckrodt Plc said its generic specialty pharmacy unit sales were down 18 percent.При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2021 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог